Dj. Tate et al., Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: Impact on local control, INT J RAD O, 45(4), 1999, pp. 915-921
Citations number
23
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Purpose: Treatment of patients with nasopharyngeal carcinoma using external
beam radiation therapy (EBRT) alone results in significant local recurrenc
e. Although intracavitary brachytherapy can be used as a component of manag
ement, it may be inadequate if there is extension of disease to the skull b
ase. To improve local control, stereotactic radiosurgery was used to boost
the primary tumor site following fractionated radiotherapy in patients with
nasopharyngeal carcinoma.
Methods and Materials: Twenty-three consecutive patients were treated with
radiosurgery following radiotherapy for nasopharyngeal carcinoma from 10/92
to 5/98. All patients had biopsy confirmation of disease prior to radiatio
n therapy; Stage III disease (1 patient), Stage IV disease (22 patients), F
ifteen patients received cisplatinum-based chemotherapy in addition to radi
otherapy. Radiosurgery was delivered using a frame-based LINAC as a boost (
range 7 to 15 Gy, median 12 Gy) following fractionated radiation therapy (r
ange 64.8 to 70 Gy, median 66 Gy).
Results: All 23 patients (100%) receiving radiosurgery as a boost following
fractionated radiation therapy are locally controlled at a mean follow-up
of 21 months (range 2 to 64 months). There have been no complications of tr
eatment caused by radiosurgery. However, eight patients (35%) have subseque
ntly developed regional or distant metastases.
Conclusions: Stereotactic radiosurgical boost following fractionated EBRT p
rovides excellent local control in advanced stage nasopharynx cancer and sh
ould be considered for all patients with this disease. The treatment is saf
e and effective and may be combined with cisplatinum-based chemotherapy. (C
) 1999 Elsevier Science Inc.